Bilthoven Biologicals, a Serum Institute of India company in the Netherlands, will partner with Bharat Biotech in the news, thereby ensuring production of more oral poliovirus vaccines (OPV). Coordinated actions will facilitate the production of a more secure and reliable supply chain of these vaccines, supporting the global anti-polio program.
The agreement between the two companies means that drug substances used in making vaccines will be sourced from Bilthoven Biologicals by Bharat Biotech. These drug substances will then be used to manufacture OPVs in India for distribution within the country and internationally.
Moreover, there is an understanding aimed at securing the regulatory approvals required to facilitate the easy commercialization of such vaccines within India.
https://akm-img-a-in.tosshub.com/businesstoday/images/story/202404/660be0b19043b-bharat-biotech–bilthoven-biologicals-join-forces-to-fortify-global-polio-eradication-efforts-024048131-16×9.png?size=948:533
In short, this is a mixed-type project that examines both firm skills. Today, as the largest manufacturer worldwide for oral polio vaccines, Bharat Biotech is recognized among the most preferred collaborators for pharmaceutical, biotechnological, and developing healthcare products and vaccines.
The company equipped the Serum Institute of India with highly advanced technology and know-how in vaccine manufacturing when it was acquired in 2012.
There are many reasons why this collaboration is important. First, it reinforces the overall supply security of OPVs. By having various production units contribute to the vaccine pool, the danger of interruptions caused by unforeseen events is minimized. Second, it supports India’s endeavors towards the total eradication of polio.
As put forward by Krishna Ella, Executive Chairman of Bharat Biotech, OPVs have been a backbone for decades within India’s immunization program, and this partnership underscores the country’s resolve towards a future with no more polio.
This project also reflects global efforts towards eradicating polio. This collaboration can help in immunization campaigns across continents by increasing access to OPVs.
The collaboration also amplifies Bharat Biotech’s existing strengths in producing polio vaccines. Its Biopolio vaccine, which has been pre-qualified by the WHO, will continue to be pivotal in combating polio diseases. According to a spokesperson from Bharat Biotech, there is no breakage in their supplies for polio vaccines.
The worldwide battle against polio remains a possible public health issue. This joint venture between Bharat Biotech and Bilthoven Biologicals is a crucial part of reaching the envisaged mission.
By sharing their talents and resources, these organizations can make a significant contribution to the eradication of polio, thereby ensuring that each child can enter adulthood in a world without polio, which tragically does not allow too many people to experience the privileges of adulthood.
